Exenatide Once Weekly for Smoking Cessation

Summary

The purpose of this study is to identify a potential new treatment for smoking cessation.

Timeline

Start

2016-07

Primary completion

2020-01-03

Completion

2020-01-03

Outcome

Met primary endpoint

paper Exenatide increased the risk for smoking abstinence compared to placebo (46.3% and 26.8%, respectively), (risk ratio [RR] = 1.70; 95% credible interval = [0.96, 3.27]; PP = 96.5%). PMID 33831213 ↗

paper Exenatide, in combination with the NRT improved smoking abstinence, reduced craving and withdrawal symptoms, and decreased weight gain among abstainers. PMID 33831213 ↗

Publications

• Background Yammine L, Kosten TR, Cinciripini PM, Green CE, Meininger JC, Minnix JA, Newton TF. Exenatide once weekly for smoking cessation: study protocol for a randomized clinical trial. Medicine (Baltimore). 2018 Jan;97(2):e9567. doi: 10.1097/MD.0000000000009567.
• Yammine L, Green CE, Kosten TR, de Dios C, Suchting R, Lane SD, Verrico CD, Schmitz JM. Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: A Pilot Randomized Controlled Trial. Nicotine Tob Res. 2021 Aug 29;23(10):1682-1690. doi: 10.1093/ntr/ntab066.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Exenatide	Peptide	2 mg	Subcutaneous
Background	Nicotine	Unknown	21 mg	Other

Indications

No indication recorded.